Sight Sciences (NASDAQ:SGHT) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Sight Sciences (NASDAQ:SGHT) in a report issued on Friday, Benzinga reports.

Sight Sciences Trading Down 2.3 %

Shares of NASDAQ:SGHT opened at $5.82 on Friday. Sight Sciences has a 1 year low of $1.04 and a 1 year high of $10.97. The business has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $4.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 12.65 and a current ratio of 13.29.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.13. The company had revenue of $18.75 million during the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 42.84%. During the same quarter in the prior year, the business earned ($0.35) earnings per share. Sell-side analysts anticipate that Sight Sciences will post -1.04 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Alison Bauerlein sold 10,123 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the transaction, the chief financial officer now owns 426,248 shares of the company’s stock, valued at approximately $2,165,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Paul Badawi sold 12,571 shares of Sight Sciences stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $63,860.68. Following the completion of the transaction, the chief executive officer now owns 5,750,729 shares in the company, valued at $29,213,703.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alison Bauerlein sold 10,123 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The disclosure for this sale can be found here. Insiders sold 34,129 shares of company stock valued at $173,375 over the last ninety days. 27.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Sight Sciences by 180.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock worth $62,000 after acquiring an additional 7,764 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Sight Sciences by 51.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after purchasing an additional 9,106 shares during the period. Boston Partners grew its holdings in Sight Sciences by 3.1% during the 3rd quarter. Boston Partners now owns 331,776 shares of the company’s stock valued at $1,117,000 after buying an additional 9,919 shares in the last quarter. Swiss National Bank increased its position in shares of Sight Sciences by 19.5% during the third quarter. Swiss National Bank now owns 69,314 shares of the company’s stock valued at $234,000 after buying an additional 11,300 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in shares of Sight Sciences by 100.0% in the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $202,000 after buying an additional 30,000 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.